| Oryzon

Skip to main content

English
Español

Company
- Overview
- Strategy
- Team
Epigenetics
- Epigenetics
- LSD1
Programs
Patients
- Clinical Trials
Investors
News & Events
- Press releases
- Events
Contact

Search

Breadcrumb

Home

5 January 2016

Oryzon to Attend the 34th Annual J.P. Morgan Healthcare Conference in San Francisco

1 October 2025

ORYZON strengthens patent portfolio for iadademstat with European grant decision covering combinations with PD1/PD-L1 inhibitors

8-9 October 2025

25th Sachs Annual Biotech in Europe Forum 2025

Mövenpick Hotel

Basel

Switzerland

7-9 October 2025

BIOSPAIN 2025

Fira de Barcelona – Montjuïc

Barcelona

Spain

7 October 2025

BME Investor Access Event 2025

Maison de la Chimie

Paris

France

30 September - 1 October 2025

Paris Midcap Event 2025

Four Seasons George V

Paris

France

25-26 September 2025

Drug Discovery Innovation Programme

Intercontinental Hotel

Barcelona

Spain

25 September 2025

ORYZON to participate in upcoming events in September and October

22 September 2025

ORYZON to sponsor first Phelan-McDermid syndrome (PMS) burden of illness study

16 September 2025

ORYZON strengthens patent portfolio for iadademstat and vafidemstat with new Decisions to Grant

Pagination

First page «
Previous page ‹
Current page 1
Page 2
Page 3
Page 4
Page 5
Page 6
Page 7
Page 8
Page 9
Next page ›
Last page »

Subscribe to

Company

Overview
Strategy
Team

Epigenetics

Epigenetics
LSD1

Programs

Pipeline
Iadademstat
Vafidemstat
Collaborations
Publications

Patients

Clinical Trials

Investors

Share Information
Financial Information
CNMV Filings
Analyst Coverage
Corporate Governance
Corporate Social Responsibility

News & Events

Press releases
Events

Contact

Contact
Email Alerts
Join us

© Oryzon Genomics, S.A. - All Rights Reserved

Legal
Privacy Policy
Cookie Policy
Ethics Channel